Immunohistochemical Character of Hepatic Angiomyolipoma: For Its Management
Figure 3
Dynamic contrast enhancement MRI with a hepatocyte-specific contrast agent (gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid). Plain T1-weighted MRI revealed a low-intensity tumor (a), arterial phase hypervascularity (b), and a defective area visible in the late phase (c) and in the hepatic cellular phase (d).